Hives News and Research RSS Feed - Hives News and Research

Hives (or Urticaria) are a kind of skin rash notable for dark red, raised, itchy bumps. Hives are frequently caused by allergic reactions; however, there are many non-allergic causes.
Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds. [More]
Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin. [More]
FDA approves Intelliject's Auvi-Q for anaphylaxis

FDA approves Intelliject's Auvi-Q for anaphylaxis

Intelliject, Inc. announced that the U.S. Food and Drug Administration approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis. This is the first-and-only compact auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process. [More]
Steak and ticks: A potentially life-threatening experience

Steak and ticks: A potentially life-threatening experience

Tick bites can trigger a severe, delayed allergic reaction to red meat, suggest findings published in the Journal of General Internal Medicine. [More]

Tips to deal with insect stings

With the start of summer comes the appearance of common stinging insects, such as bees, wasps, hornets and yellowjackets, and the various related health risks that range from irritating but relatively harmless stings to the threat of serious allergic reaction. The National Pest Management Association (NPMA) stresses that when it comes to stinging insects, the best way to avoid the associated health risks is to practice simple prevention and treatment tips. [More]
Linagliptin safe and effective for African American patients with type 2 diabetes

Linagliptin safe and effective for African American patients with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African American adult patients with type 2 diabetes whose blood sugar was not adequately controlled. [More]
Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents. [More]

CAPE arrests growth of prostate cancer tumors

Could it be that a remedy from thousands of years ago holds the secret to stopping prostate cancer? A newly published study furthers the exploration of caffeic acid phenethyl ester (CAPE) and its potential anticarcinogen and antioxidant properties. The demonstrated ability of CAPE to stop prostate cancer tumors from growing may soon have it earning a spot among other natural remedies for prostate cancer treatment. [More]
CAPE arrests growth of prostate cancer cells and tumors in mice

CAPE arrests growth of prostate cancer cells and tumors in mice

An over-the-counter natural remedy derived from honeybee hives arrests the growth of prostate cancer cells and tumors in mice, according to a new paper from researchers at the University of Chicago Medicine. [More]
Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder. [More]

Crispy brand cookies may contain undeclared allergens, warns FDA

TWI Foods Inc. is voluntarily recalling several varieties of Crispy brand cookies and rusk. The Food and Drug Administration (FDA) along with the Canadian Food Inspection Agency (CFIA) and TWI Foods Inc., are warning people with allergies to milk or almonds not to consume Crispy brand cookie and rusk products. The affected products contain almonds and/or milk which are not clearly declared on the label. [More]
Allergy-free egg in the making

Allergy-free egg in the making

Researchers at CSIRO and experts at Geelong's Deakin University have found a way to “switch off” four egg allergens. These modified eggs could produce chickens that lay hypoallergenic eggs but the genes and DNA of the chicken would remain unaltered. [More]

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S. [More]

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. [More]
EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies. [More]
Researchers warn food allergy blood tests should never be used as standalone diagnostics

Researchers warn food allergy blood tests should never be used as standalone diagnostics

An advisory from two leading allergists, Robert Wood of the Johns Hopkins Children's Center and Scott Sicherer of Mt. Sinai Hospital in New York, urges clinicians to use caution when ordering allergy tests and to avoid making a diagnosis based solely on test results. [More]
Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases. [More]
Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif. [More]

Frozen ground tuna recalled by Osamu Corporation

Osamu Corporation of Gardena, CA is recalling up to 1,800 cases, lot# 7013, of frozen ground tuna because the FDA found decomposition in several samples of the product and also found elevated histamine levels in samples taken from one retail location. [More]

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes. [More]